Koomen E R, Joosse A, Herings R M C, Casparie M K, Bergman W, Nijsten T, Guchelaar H J
Department of Clinical Pharmacy & Toxicology, Leiden University Medical Centre, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
Eur J Cancer. 2007 Nov;43(17):2580-9. doi: 10.1016/j.ejca.2007.09.004. Epub 2007 Oct 22.
Statins show anticancer activity in melanoma cells. We investigated the association between statins and incidence and Breslow thickness of cutaneous melanoma (CM).
Data were used from PHARMO, a pharmacy database, and PALGA, a pathological database, in the Netherlands. Cases had a primary CM diagnosis between January 1st 1991 and December 14th 2004, were 18 years and had 3 years of follow up in PHARMO before CM diagnosis. Controls were matched for gender, date of birth and geographic region. Analyses were adjusted for age, gender, year of diagnosis, number of medical diagnoses and the use of NSAIDs and oestrogens.
Finally, 1318 cases and 6786 controls were selected. CM risk was not associated with statin use (> or = 0.5 years) (adjusted odds ratio (OR)=0.98, 95% confidence interval (CI)=0.78-1.2). However, statin use was associated with a reduced Breslow thickness (-19%, 95% CI=-33, -2.3, p=0.03).
Our study suggests protective effects of statins on melanoma progression.
他汀类药物在黑色素瘤细胞中显示出抗癌活性。我们研究了他汀类药物与皮肤黑色素瘤（CM）的发病率和 Breslow 厚度之间的关联。
使用了荷兰的药房数据库 PHARMO 和病理数据库 PALGA 中的数据。病例在 1991 年 1 月 1 日至 2004 年 12 月 14 日期间被诊断为原发性 CM，年龄在 18 岁及以上，并且在 PHARMO 中 CM 诊断前有 3 年的随访记录。对照组在性别、出生日期和地理区域方面进行了匹配。分析对年龄、性别、诊断年份、医疗诊断数量以及非甾体抗炎药和雌激素的使用进行了调整。
最终，选择了 1318 例病例和 6786 例对照。CM 风险与他汀类药物使用（≥0.5 年）无关（调整后的优势比（OR）=0.98，95%置信区间（CI）=0.78 - 1.2）。然而，他汀类药物的使用与 Breslow 厚度降低相关（-19%，95%CI=-33，-2.3，p = 0.03）。
我们的研究表明他汀类药物对黑色素瘤进展具有保护作用。
